Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Research & Development of $8.8 million for Q1 2026, up 11.54% on a QoQ basis from $7.9 million in Q4 2025, and up 13.29% year-over-year from $7.8 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Research & Development history runs 7 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- Quarterly Research & Development rose 13.29% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.2 million (up 26.29% YoY) and the FY2025 annual result came in at $31.2 million, up 21.93% from the prior year.
- Research & Development was $8.8 million for Q1 2026 at Xeris Biopharma Holdings, up from $7.9 million in the prior quarter.
- Across five years, Research & Development topped out at $8.8 million in Q1 2026 and bottomed at $3.7 million in Q2 2022.
- A 5-year average of $6.4 million and a median of $6.1 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slumped 50.85% — and 2023, when it soared 63.72%.
- Xeris Biopharma Holdings' Research & Development stood at $5.0 million in 2022, then increased by 28.8% to $6.4 million in 2023, then fell by 4.54% to $6.1 million in 2024, then grew by 29.25% to $7.9 million in 2025, then increased by 11.54% to $8.8 million in 2026.
- Business Quant data shows XERS's Research & Development at $8.8 million in Q1 2026, $7.9 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 8.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.78 Mn |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | 7.48 Mn |
| Jun 30, 2025 | 8.06 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 7.82 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 6.04 Mn |
| Jun 30, 2022 | 3.72 Mn |
| Mar 31, 2022 | 6.25 Mn |
| Dec 31, 2021 | 10.08 Mn |
| Sep 30, 2021 | 5.66 Mn |
| Jun 30, 2021 | 5.38 Mn |